Literature DB >> 34071109

MicroRNA 320, an Anti-Oncogene Target miRNA for Cancer Therapy.

Yuanyuan Liang1, Shun Li2,3, Liling Tang1.   

Abstract

MicroRNAs are a set of highly conserved non-coding RNAs that control gene expression at the post-transcriptional/translational levels by binding to the 3'-UTR of diverse target genes. Increasing evidence indicates that miRNAs not only play a vital role in many biological processes, but they are also frequently deregulated in pathological conditions, including cancer. The miR-320 family is one of many tumor suppressor families and is composed of five members, which has been demonstrated to be related to the repression of epithelial-mesenchymal transition (EMT) inhibition, cell proliferation, and apoptosis. Moreover, this family has been shown to regulate drug resistance, and act as a potential biomarker for the diagnosis, prognosis, and prediction of cancer. In this review, we summarized recent research with reference to the tumor suppressor function of miR-320 and the regulation mechanisms of miR-320 expression. The collected evidence shown here supports that miR-320 may act as a novel biomarker for cancer prognosis and therapeutic response to cancer treatment.

Entities:  

Keywords:  EMT; biomarker; miR-320; therapeutic sensitivity; tumor-suppressive

Year:  2021        PMID: 34071109     DOI: 10.3390/biomedicines9060591

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  106 in total

1.  microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients.

Authors:  Luigi Mari; Sanne J M Hoefnagel; Domenico Zito; Marian van de Meent; Peter van Endert; Silvia Calpe; Maria Del Carmen Sancho Serra; Mirjam H M Heemskerk; Hanneke W M van Laarhoven; Maarten C C M Hulshof; Susanne S Gisbertz; Jan Paul Medema; Mark I van Berge Henegouwen; Sybren L Meijer; Jacques J G H M Bergman; Francesca Milano; Kausilia K Krishnadath
Journal:  Gastroenterology       Date:  2018-06-07       Impact factor: 22.682

Review 2.  Epigenetic activation of tumor suppressor microRNAs in human cancer cells.

Authors:  Yoshimasa Saito; Peter A Jones
Journal:  Cell Cycle       Date:  2006-10-01       Impact factor: 4.534

3.  Cell cycle-targeting microRNAs promote differentiation by enforcing cell-cycle exit.

Authors:  Tobias Otto; Sheyla V Candido; Mary S Pilarz; Ewa Sicinska; Roderick T Bronson; Michaela Bowden; Iga A Lachowicz; Kristin Mulry; Anne Fassl; Richard C Han; Emmanuelle S Jecrois; Piotr Sicinski
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-18       Impact factor: 11.205

4.  Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis.

Authors:  Zhuochao Zhang; Xiao Li; Wei Sun; Shuqiang Yue; Jingyue Yang; Junjie Li; Ben Ma; Jianlin Wang; Xisheng Yang; Meng Pu; Bai Ruan; Ge Zhao; Qike Huang; Lin Wang; Kaishan Tao; Kefeng Dou
Journal:  Cancer Lett       Date:  2017-03-10       Impact factor: 8.679

5.  MiR-320a inhibits malignant phenotype of melanoma cells via targeting PBX3.

Authors:  Guili Fu; Jingjing Lu; Yuanquan Zheng; Pan Wang; Qin Shen
Journal:  J BUON       Date:  2020 Jul-Aug       Impact factor: 2.533

6.  MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ.

Authors:  Mingrong Lü; Keshuo Ding; Guofeng Zhang; Mianmian Yin; Guidong Yao; Hui Tian; Jie Lian; Lin Liu; Meng Liang; Tao Zhu; Fei Sun
Journal:  Sci Rep       Date:  2015-03-04       Impact factor: 4.379

7.  LncRNA SNHG12 contributes proliferation, invasion and epithelial-mesenchymal transition of pancreatic cancer cells by absorbing miRNA-320b.

Authors:  Wei Cao; Guoxiong Zhou
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

8.  Circular RNA CircMAP3K5 Acts as a MicroRNA-22-3p Sponge to Promote Resolution of Intimal Hyperplasia Via TET2-Mediated Smooth Muscle Cell Differentiation.

Authors:  Zhi Zeng; Luoxing Xia; Shunyang Fan; Junmeng Zheng; Jinhong Qin; Xuejiao Fan; Yunfeng Liu; Jun Tao; Yingying Liu; Kang Li; Zhenwei Ling; Yun Bu; Kathleen A Martin; John Hwa; Renjing Liu; Wai Ho Tang
Journal:  Circulation       Date:  2020-11-19       Impact factor: 29.690

9.  GNAI1 Suppresses Tumor Cell Migration and Invasion and is Post-Transcriptionally Regulated by Mir-320a/c/d in Hepatocellular Carcinoma.

Authors:  Jian Yao; Lin-Hui Liang; Yu Zhang; Jie Ding; Qi Tian; Jin-Jun Li; Xiang-Huo He
Journal:  Cancer Biol Med       Date:  2012-12       Impact factor: 4.248

View more
  5 in total

Review 1.  The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract.

Authors:  William Frank Ferris
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

Review 2.  Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.

Authors:  Tomas Koltai; Stephan Joel Reshkin; Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Khalid Omer Alfarouk; Rosa Angela Cardone
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

Review 3.  The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer.

Authors:  Michał Szczyrek; Paulina Bitkowska; Marta Jutrzenka; Janusz Milanowski
Journal:  J Pers Med       Date:  2022-07-27

4.  MiR-320-3p Regulates the Proliferation and Differentiation of Myogenic Progenitor Cells by Modulating Actin Remodeling.

Authors:  Mai Thi Nguyen; Wan Lee
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

5.  Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort.

Authors:  Shabana Amanda Ali; Osvaldo Espin-Garcia; Andy K Wong; Pratibha Potla; Chiara Pastrello; Madison McIntyre; Starlee Lively; Igor Jurisica; Rajiv Gandhi; Mohit Kapoor
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-03-18       Impact factor: 5.346

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.